Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study
September 17, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the approval by the Board of Directors for a Patient...
Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Disease Symptoms
September 15, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today the publication in the current issue of the peer reviewed Journal of Clinical and Cellular...
Photo Release -- Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey
August 27, 2015 08:30 ET
|
AIM ImmunoTech Inc.
NEW BRUNSWICK, N.J., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the...
Hemispherx Receives the European Patent Office Examining Division's Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen(R) Formulations
June 25, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 25, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on June 18, 2015, that the European...
Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)
May 26, 2015 12:46 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
May 11, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
March 24, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 24, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European subsidiary, "Hemispherx Biopharma Europe...
Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus
March 23, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") will present integrated findings of new studies of Ampligen®...
Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand
March 09, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 9, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Emerge Health Pty Ltd....
Hemispherx Biopharma: Institute of Medicine, the Health Arm of the US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) as a "Systemic Exertion Intolerance Disease" (SEID)
February 23, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced today that a new report, issued February 10, 2015 by the Institute of...